Digoxin (Digoxin) Patent Expiration, LOE Window & CMS Spending

Digoxin (Digoxin) by Hikma Pharmaceuticals: Off-Patent Genericized (AB Competition), 5 AB generics, $40.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN021648 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$40.7M
2024 Medicare Part D Spend$36.9M
2024 Medicaid Spend$3.8M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.